Success Story: We Helped a Biotechnology Researcher Secure NIW Approval for Work on Next-Generation RNA Therapeutics
Client’s Testimonial:
"B and Chen immigration team were so helpful and dedicated during the I-140 preparation process. Questions were answered quickly and promptly. All the instructions were given step-by-step in a very comprehensive way. Totally satisfied at this stage!
On June 1st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Director of Biology in the Field of Biotechnology (Approval Notice).
General Field: Biotechnology
Position at the Time of Case Filing: Director of Biology
Country of Origin: Vietnam
Country of Residence at the Time of Filing: Australia
Approval Notice Date: June 1st, 2026
Processing Time: 27 months, 11 days
Case Summary:
The development of effective treatments for complex diseases often depends on the ability to precisely target the biological mechanisms that drive them. For patients affected by cancer, type 2 diabetes, Duchenne muscular dystrophy (DMD), multiple sclerosis (MS), and other serious conditions, advances in genetic medicine can create opportunities that traditional therapies cannot provide. The client has dedicated his career to helping advance these possibilities through biotechnology research.
We are pleased to celebrate the approval of the client’s I-140 National Interest Waiver petition. Holding a Ph.D. in molecular and biomedical sciences, the client is an expert in biotechnology whose proposed endeavor is to continue developing state-of-the-art synthetic oligonucleotide-based therapies, novel chemically modified oligonucleotides, and advanced biological evaluation systems to expand treatment options for both common and rare diseases.
At the time of filing, the client planned to continue working as a research scientist in the biotechnology sector, focusing on therapeutic antisense oligonucleotides and other precision medicine approaches designed to correct genetic abnormalities or modify disease-causing gene expression. The petition demonstrated that this endeavor possesses substantial merit and national importance because it addresses diseases that impose significant health and economic burdens while contributing to the advancement of biotechnology, a field recognized as strategically important to U.S. innovation and technological leadership.
Research Excellence and Scientific Recognition
The client's qualifications were supported by a record of scholarly achievement that demonstrated both productivity and growing influence within the field:
- 21 peer-reviewed journal articles, including 12 first-authored publications
- 1 patent related to biotechnology innovation
- 398 citations to his published work
Completion of a peer review service for an authoritative journal in the field
- Research funding support from the Perron Institute for Neurological and Translational Science, MS Research Australia, and the McCusker Charitable Foundation
NIW Approval and Outlook
To establish the client's significance under the National Interest Waiver framework, we connected his scholarly record, citation influence, funded research, patent activity, and future plans to a nationally important endeavor focused on expanding treatment options for serious diseases. The evidence showed not only that the client had already contributed meaningful advances to biotechnology but also that he was well-positioned to continue producing work with broad public-health benefits.
We are honored to have assisted the client in obtaining NIW approval and look forward to the continued impact of his research on precision medicine, genetic therapies, and the development of innovative treatments for patients facing challenging diseases.